DCT

5:23-cv-06360

ChromaCode Inc v. Bio Rad Laboratories Inc

Log In
Key Events
Amended Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 5:23-cv-06360, N.D. Cal., 03/27/2024
  • Venue Allegations: Venue is alleged to be proper in the Northern District of California because Defendant Bio-Rad Laboratories, Inc. maintains its headquarters and a regular and established place of business in the district, and offers for sale and sells the accused products there.
  • Core Dispute: Plaintiffs allege that Defendant's Droplet Digital PCR systems infringe patents related to methods for detecting a greater number of biological targets than the number of available fluorescent colors by using cumulative signal intensity.
  • Technical Context: The technology addresses a fundamental limitation in molecular diagnostics, enabling more comprehensive and efficient analysis of biological samples, which is significant for research and clinical applications like cancer detection.
  • Key Procedural History: The complaint alleges that Plaintiff ChromaCode is the exclusive licensee of the asserted patents from Plaintiff California Institute of Technology. It further alleges that Bio-Rad had pre-suit knowledge of ChromaCode's technology and patent rights through fundraising discussions and presentations occurring in 2014, 2017, and 2018, which may be relevant to the allegations of willful infringement.

Case Timeline

Date Event
2011-03-18 Bio-Rad files provisional patent application for its own multiplexing technology (U.S. No. 61/454,373)
2012-02-03 Earliest priority date for '051, '170, and '921 Patents
2014-01-01 ChromaCode and Bio-Rad hold fundraising discussions
2015-02-26 Patent application for the '051 Patent is published
2015-06-08 ChromaCode obtains exclusive license from Caltech for the HDPCR Patents
2018-09-04 '051 Patent is issued
2018-09-04 '170 Patent is issued
2022-12-14 Bio-Rad offers QX600 System for sale
2023-11-28 '921 Patent is issued
2024-03-27 Second Amended Complaint is filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,068,051 - "Signal Encoding and Decoding in Multiplexed Biochemical Assays," issued September 4, 2018

  • The Invention Explained:

    • Problem Addressed: Traditional methods for detecting multiple biological targets (analytes) in a single sample are limited by the number of unique fluorescent colors that can be reliably distinguished Compl. ¶¶8-9 Compl. ¶14 This phenomenon, known as "spectral overlap," restricts the "multiplexing" capacity of conventional assays, as each target typically requires its own unique color for identification Compl. ¶¶14-15
    • The Patented Solution: The invention describes a method to overcome the one-target-one-color barrier by using a limited number of fluorescent colors (fluorophores) to unambiguously identify a much larger number of analytes Compl. ¶¶16, 22 It achieves this through a coding scheme where the presence of an analyte is encoded not just by a specific color, but by a contribution to the cumulative intensity of signals across multiple color channels '051 Patent, abstract '051 Patent, col. 2:54-66 By measuring the total signal intensity in each color channel, a unique signature is generated that can be decoded to determine the specific combination of multiple analytes present, even if M (analytes) is greater than F (fluorophores) '051 Patent, col. 4:1-65
    • Technical Importance: This "High-Definition PCR" (HDPCR) approach enables faster, less expensive, and more comprehensive diagnostic tests from a single, small biological sample Compl. ¶¶10, 23-24

  • Key Claims at a Glance:

    • The complaint asserts independent claim 1 Compl. ¶51
    • The essential elements of independent claim 1 are:
      • A method of detecting the presence or absence of at least seven polynucleotide analytes in a single sample solution volume.
      • Providing a sample solution containing at least seven hybridization probes, where each probe corresponds to one of the analytes, and each probe has at least one fluorophore selected from four fluorophores.
      • Each probe, when excited and contacted with its analyte, generates a cumulative intensity signal.
      • Contacting the sample with the probes and exciting them to generate the cumulative intensity signal(s).
      • Measuring the cumulative intensity signal(s) to generate a measurement that "non-degenerately indicates" the presence or absence of the at least seven analytes.
      • The method non-degenerately detects the analytes without requiring immobilization, physical separation, or mass spectrometry.
    • The complaint does not explicitly reserve the right to assert dependent claims, but this is standard practice.

U.S. Patent No. 10,770,170 - "Signal Encoding and Decoding in Multiplexed Biochemical Assays," issued September 8, 2020

  • The Invention Explained:

    • Problem Addressed: As with the '051 Patent, the invention addresses the limitations of traditional fluorescent assays where the number of detectable targets is constrained by the number of available, spectrally distinct colors Compl. ¶¶13-15 The shared specification notes the need for multiplexed reactions that can be carried out in a single solution '170 Patent, col. 1:30-41
    • The Patented Solution: The '170 Patent, which shares a specification with the '051 Patent, claims a method applying the same core principle of using cumulative intensity measurements to detect more analytes than available colors. This patent specifically claims a method involving partitioning a sample mixture into a plurality of droplets, a key feature of Droplet Digital PCR (ddPCR) technology '170 Patent, col. 11:26-28 Within these droplets, analytes are detected by measuring cumulative signals from a set of hybridization probes comprising "at most four fluorophores" to identify "at least five polynucleotide analytes" '170 Patent, col. 11:26-28 '170 Patent, col. 12:1-15
    • Technical Importance: The invention is particularly relevant to the ddPCR market, enabling higher-plex assays on established instrument platforms Compl. ¶19

  • Key Claims at a Glance:

    • The complaint asserts independent claim 1 Compl. ¶62
    • The essential elements of independent claim 1 are:
      • A method of "unambiguously detecting" any unique combination of at least five polynucleotide analytes in a plurality of droplets.
      • Forming a mixture of the sample and at least five hybridization probes, where each probe comprises at least one fluorophore and at most four fluorophores.
      • Partitioning the mixture into a plurality of droplets.
      • Exciting the fluorophore(s) to generate signals.
      • Measuring the signals to generate a cumulative intensity measurement that corresponds to a unique combination of the analytes.
      • Determining the presence or absence of each analyte based on the cumulative intensity measurement.
      • The method does not require immobilization or mass spectrometry.
    • The complaint does not explicitly reserve the right to assert dependent claims.

Multi-Patent Capsule

  • U.S. Patent No. 11,827,921: "Signal Encoding and Decoding in Multiplexed Biochemical Assays," issued November 28, 2023
    • Technology Synopsis: The '921 Patent, which shares the same specification as the '051 and '170 patents, claims an assay that solves the problem of limited multiplexing Compl. ¶33 The solution is an assay capable of unambiguously detecting M analytes using a fluorescent signal with only F wavelength components, where M is greater than F '921 Patent, col. 12:25-28 '921 Patent, col. 13:1-8
    • Asserted Claims: Independent claim 1 Compl. ¶73
    • Accused Features: The complaint alleges that Bio-Rad's QX600 System, when performing amplitude-based PCR multiplexing, practices the claimed assay by identifying M analytes encoded as values of a fluorescent signal with F wavelength components, where M > F Compl. ¶73

III. The Accused Instrumentality

  • Product Identification: The accused instrumentalities are Defendant's QX600 Droplet Digital PCR System and QX ONE Droplet Digital PCR System, along with related systems, components, and assays, such as the ddPCR Multiplex Supermix Compl. ¶39, fn. 6 Compl. ¶46
  • Functionality and Market Context:
    • The accused products are digital PCR systems that perform what Bio-Rad terms "Amplitude multiplexing" Compl. ¶43 This functionality allows the systems to detect and quantify a number of biological targets that exceeds the number of distinct fluorescent color channels available in the instrument Compl. ¶¶43, 45
    • Specifically, the QX600 System is advertised as using its six-color detection capability to quantify up to 12 targets in a single well Compl. ¶41 The QX ONE system is described as using four color channels to detect as many as eight targets Compl. ¶46
    • The complaint alleges this capability of detecting more targets than colors is a core feature that infringes the asserted patents (Compl. ¶45). A Bio-Rad marketing bulletin for the QX600 System, referenced in the complaint, includes a figure showing data plots titled "Quantification of 12 Targets in a Single Well" using the system's six fluorescence channels, which Plaintiffs present as evidence of the infringing capability Compl. p. 17

IV. Analysis of Infringement Allegations

'051 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of detecting the presence or absence of at least seven polynucleotide analytes... in a single sample solution volume The accused QX600 and QX ONE systems are advertised as quantifying up to 12 and 8 targets, respectively, in a single well, which constitutes a single sample solution volume. ¶41; ¶46; ¶51 col. 28:26-33
comprising at least seven hybridization probes, each hybridization probe corresponding to one of the at least seven polynucleotide analytes, wherein each hybridization probe comprises at least one fluorophore selected from four fluorophores The accused systems operate with assays using multiple probes. The QX600 uses six fluorophores, and the QX ONE uses four, both of which satisfy the "selected from four fluorophores" language for the accused 8- and 12-target assays. ¶41; ¶46; ¶51 col. 7:40-44
generates a cumulative intensity signal The accused systems' "Amplitude multiplex" functionality operates by generating a cumulative signal from each fluorophore to create an encoding scheme. ¶43; ¶45 col. 2:54-66
measuring the cumulative intensity signal(s), thereby generating a cumulative signal measurement, wherein the cumulative signal measurement non-degenerately indicates the presence or absence of the at least seven polynucleotide analytes Bio-Rad's "Amplitude multiplexing" is alleged to be a method that uses the cumulative signal to unambiguously (non-degenerately) identify more targets than there are colors, thereby indicating the presence or absence of each analyte. ¶43; ¶51 col. 14:35-44
wherein said method non-degenerately detects the presence or absence of the at least seven polynucleotide analytes... without requiring any step of immobilization..., physical separation..., or mass spectrometry The accused ddPCR systems are solution-based assays performed in a single volume (partitioned into droplets) that do not require these steps. ¶39; ¶41 col. 11:13-18

'170 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of unambiguously detecting any unique combination of presence or absence of at least five polynucleotide analytes in a plurality of droplets The accused ddPCR systems partition samples into droplets and are advertised as unambiguously detecting up to 12 targets (QX600) or 8 targets (QX ONE). ¶41; ¶46; ¶62 col. 11:26-28
forming a mixture of said sample and at least five hybridization probes, wherein each of said at least five hybridization probes further comprises at least one fluorophore and at most four fluorophores The accused systems use probe-based assays. The QX ONE system uses exactly four fluorophores to detect eight targets, directly corresponding to this limitation. ¶46; ¶62 col. 12:2-5
partitioning said mixture into said plurality of droplets This is the fundamental operating principle of the accused "Droplet Digital PCR" systems. ¶39; ¶41 col. 12:5-6
measuring said one or more signals to generate a cumulative intensity measurement, wherein said cumulative intensity measurement corresponds to the presence of a unique combination... of said at least five polynucleotide analytes The accused systems' "Amplitude multiplexing" is alleged to rely on measuring cumulative signal intensity to uniquely identify the combination of analytes present. ¶43; ¶45; ¶62 col. 12:9-12
determining whether each of said least five polynucleotide analytes is present... based on said cumulative intensity measurement The accused systems' software allegedly decodes the cumulative intensity measurement to determine the presence of each target analyte. ¶43; ¶45; ¶62 col. 12:12-15
  • Identified Points of Contention:
    • Scope Questions: A central dispute may be whether the term "non-degenerately indicates" (in the '051 Patent) and "unambiguously detecting" (in the '170 Patent) can be read to cover the specific "Amplitude multiplexing" algorithms and signal processing methods used by the accused Bio-Rad systems. The defense may argue that its method of resolving signal overlap is technically distinct from the coding schemes described in the patents.
    • Technical Questions: The case will likely require expert testimony to establish whether the accused systems' method of combining and measuring fluorescent signals to identify analytes is technically equivalent to the claimed "cumulative intensity signal measurement." The complaint presents Bio-Rad's marketing materials as evidence, but the precise technical operation of the accused system will be a key factual question.

V. Key Claim Terms for Construction

  • The Term: "non-degenerately indicates" ('051 Patent) / "unambiguously detecting" ('170 Patent)
  • Context and Importance: These terms are at the heart of the dispute. Infringement hinges on whether Bio-Rad's "amplitude multiplexing" achieves detection in a manner that is "non-degenerate" or "unambiguous" as defined by the patents. Practitioners may focus on this term because it distinguishes the invention from prior art that suffered from ambiguous signal overlap and is the basis for the patents' core assertion of novelty (M > F).
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification suggests a functional definition, describing the outcome of non-degenerate detection and providing methods to achieve it, such as by designing a coding scheme to eliminate degenerate results '051 Patent, col. 14:35-44 '051 Patent, col. 17:15-28 This could support an interpretation that any method achieving this unambiguous result infringes, regardless of the specific algorithm.
    • Evidence for a Narrower Interpretation: The patents describe specific methods for creating non-degenerate "coding schemes," including enumerating results and eliminating potential analyte codes that cause ambiguity '051 Patent, col. 17:29-53 A defendant might argue these terms are limited to assays that employ such an explicit, pre-defined coding and decoding matrix, potentially distinguishing it from a real-time signal processing algorithm.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges induced infringement, stating that Bio-Rad's user guides and product instructions (e.g., the "QX600 System User Guide") expressly instruct and encourage customers to use the accused systems in a manner that directly infringes the asserted claims Compl. ¶52 Compl. ¶63 Compl. ¶74
  • Willful Infringement: The willfulness allegations are based on alleged pre-suit knowledge. The complaint asserts that Bio-Rad was made aware of ChromaCode's patented and proprietary HDPCR technology during fundraising discussions in 2014, and in further discussions and slide presentations in 2017 and 2018, prior to the launch of the accused products Compl. ¶¶37-38 The complaint also notes the 2015 publication of the application leading to the '051 Patent as providing notice Compl. ¶38 Compl. ¶55 Compl. ¶66 Compl. ¶77

VII. Analyst's Conclusion: Key Questions for the Case

  1. A central issue will be one of claim construction: will the court define the core concepts of "non-degenerately indicates" and "unambiguously detecting" functionally, based on the outcome of identifying more targets than colors, or will it limit the claims to the specific types of mathematical "coding schemes" described in the patent specifications?
  2. A key evidentiary question will be one of technical equivalence: does the accused "Amplitude multiplexing" technology operate by generating and measuring a "cumulative intensity signal" in the manner required by the claims, or does it employ a fundamentally different signal processing method to distinguish analytes that falls outside the patent's scope?
  3. A pivotal question for damages will be one of intent: can Plaintiffs prove that the alleged pre-suit discussions and technology disclosures provided Bio-Rad with the requisite knowledge of infringement to support a finding of willfulness, potentially leading to enhanced damages?
Loading Amended Complaint